Robert A. Lenz - 14 Sep 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role: Head of R&D
Signature: /s/ Joshua Pinto, as Attorney-in-Fact for Robert A. Lenz
Issuer symbol: NMRA
Transactions as of: 14 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Sep 2023, 17:58:10 UTC
Next filing: 16 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NMRA	Common Stock	Award	$0	+352,941		$0.000000	352,941	14 Sep 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NMRA	Stock Option (Right to Buy)	Award	$0	+502,934		$0.000000	502,934	14 Sep 2023	Common Stock	502,934	$17.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on September 11 of each year, with the first 1/4th vesting on September 11, 2024.
F2	25% of the shares subject to the option vest on the first anniversary measured from September 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.